Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy
Povetacicept had substantial, sustained UPCR reductions with stable eGFR, significant Gd-IgA1 reductions, hematuria resolution, clinical remission, with favorable safety in IgAN. Similar results were observed in pMN. By inhibiting both BAFF and APRIL, povetacicept targets the underlying cause of disease and has potential to provide a significant therapeutic advancement for autoimmune glomerular diseases.
Authors
- Ju-Young Moon (ORCID: https://orcid.org/0000-0003-3244-8371)
- Heather Thomas
- Sung Gyun Kim (ORCID: https://orcid.org/0000-0002-5034-0527)
- Inwhee Park (ORCID: https://orcid.org/0000-0002-9912-5393)
- Sreedhar Mandayam (ORCID: https://orcid.org/0000-0001-9044-012X)
- Jason C. Sanders
- Rajesh Yalavarthy
- Frank B. Cortazar (ORCID: https://orcid.org/0000-0003-4532-5039)
- Stanford L. Peng (ORCID: https://orcid.org/0000-0001-7445-2542)
- Yih‐Chieh Chen
- Amanda Enstrom (ORCID: https://orcid.org/0000-0001-8293-4795)
- Dong Ki Kim (ORCID: https://orcid.org/0000-0002-5342-1197)
- Ogo Egbuna (ORCID: https://orcid.org/0000-0003-0548-3809)
- Arvind Madan
- Jiahua Li (ORCID: https://orcid.org/0000-0001-7597-8829)
- James A. Tumlin
Institutions
- University of Central Florida (US)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- Seoul National University Hospital (KR)
- Kyung Hee University Hospital at Gangdong (KR)
- Hallym University Sacred Heart Hospital (KR)
- Ajou University (KR)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1016/j.ekir.2025.10.029
- Citations
- 2
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.86